top of page
THE PROJECT
Sygnature Discovery has acquired SB Drug Discovery, a specialist in ion channel and receptor drug discovery research.
January 2023
Deal announcement
Five Arrows
Investor
THE WORK
Sygnature Discovery completes acquisition of SB Drug Discovery, a world leading provider of ion channel and receptor drug discovery research delivering cell line generation and compound screening solutions in neuroscience and other therapeutic indications. This transaction, following investment from Five Arrows in summer 2021, offers a strategic advantage for both companies, to enable further expansion of the businesses and their capabilities, and forms part of Sygnature’s strategic plan to continuously invest in the expansion of its leading integrated drug discovery solutions.
THE NEWS
bottom of page